Dynorphin A
Overview
Dynorphin A is an endogenous opioid peptide of 17 amino acids that preferentially binds to and activates kappa-opioid receptors, though it also has affinity for mu and delta receptors at higher concentrations. It is derived from the precursor protein prodynorphin and plays a complex role in pain modulation, stress responses, and dysphoria. Unlike mu-opioid agonists, kappa receptor activation can produce analgesia without typical euphoria but may induce aversive psychological effects. Dynorphin also has non-opioid actions at high concentrations, including NMDA receptor modulation.
Key Research Findings
Dynorphin A has been extensively studied in preclinical models to characterize endogenous pain pathways and kappa-opioid receptor function. Elevated dynorphin levels have been associated with chronic pain states and stress-induced hyperalgesia in animal studies. Clinical development of dynorphin itself as a therapeutic has not advanced due to poor stability, blood-brain barrier penetration challenges, and complex receptor pharmacology.
Endogenous peptide
Research Phase
Interested in Dynorphin A?
Find a verified provider experienced with Dynorphin A protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Dynorphin A ProviderRelated Peptides
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone snail Conus magus. Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord, inhibiting neurotransmitter release from primary afferent nociceptive neurons. It provides analgesia without opioid receptor activation, tolerance development, or respiratory depression.
Difelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing peripheral analgesia and anti-pruritic effects without central opioid side effects such as euphoria, dysphoria, sedation, or addiction. Difelikefalin activates kappa receptors on peripheral sensory neurons and immune cells to reduce itch signaling and inflammation. Its restricted CNS penetration is a deliberate design feature to avoid abuse potential.
ARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis. It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.
Palmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to tissue damage and inflammation. PEA acts primarily through peroxisome proliferator-activated receptor alpha (PPAR-alpha), downregulating mast cell activation and pro-inflammatory mediator release. It also modulates the endocannabinoid system via the entourage effect, enhancing anandamide activity at CB1/CB2 receptors and TRPV1 channels without directly binding cannabinoid receptors.